These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 175400)

  • 1. The effect of non-steroid anti-inflammatory drugs, dibutyryl cyclic 3',5'-adenosine monophosphate and phosphodiesterase inhibitors on platelet aggregation and the platelet release reaction in normal and essential fatty acid deficient rats.
    Vincent JE; Zijlstra FJ; Bonta IL
    Prostaglandins; 1975 Nov; 10(5):899-911. PubMed ID: 175400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of separated forms of human platelet cyclic nucleotide phosphodiesterase by platelet aggregation inhibitors.
    Asano T; Ochiai Y; Hidaka H
    Mol Pharmacol; 1977 May; 13(3):400-6. PubMed ID: 195193
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential effect of platelet inhibitors in normal and in hypercholesterolaemic subjects.
    Aviram M; Winterstein G; Brook JG
    Br J Clin Pharmacol; 1985 Jun; 19(6):715-9. PubMed ID: 2992558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
    Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
    Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substances that increase the cyclic AMP content prevent platelet aggregation and the concurrent release of pharmacologically active substances evoked by arachidonic acid.
    Vargaftig BB; Chignard M
    Agents Actions; 1975 May; 5(2):137-44. PubMed ID: 51579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of inhibitors of platelet release and aggregation.
    Rosenberg JC; Sell TL
    Arch Surg; 1975 Aug; 110(8):980-3. PubMed ID: 168838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of drugs on platelet function.
    Morse EE
    Ann Clin Lab Sci; 1977; 7(1):68-72. PubMed ID: 189670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biphasic effects of phospholipase A2 on platelet aggregation. Effect of prostaglandin synthesis inhibitors and essential fatty acid deficiency.
    Vincent JE; Zijlstra FJ
    Prostaglandins; 1976 Dec; 12(6):971-9. PubMed ID: 1005744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.
    Moncada S; Korbut R
    Lancet; 1978 Jun; 1(8077):1286-9. PubMed ID: 78050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic AMP and platelet prostaglandin synthesis.
    Gerrard JM; Peller JD; Krick TP; White JG
    Prostaglandins; 1977 Jul; 14(1):39-50. PubMed ID: 197570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
    Zahavi M; Zahavi J; Kakkar VV
    Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High concentrations of arachidonic acid induce platelet aggregation and serotonin release independent of prostaglandin endoperoxides and thromboxane A2.
    Hashimoto Y; Naito C; Kume S; Kato H; Watanabe T; Kawamura M; Teramoto T; Oka H
    Biochim Biophys Acta; 1985 Sep; 841(3):283-91. PubMed ID: 2992603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interrelation of prostaglandin endoperoxide (prostaglandin G2) and cyclic 3',5'-adenosine monophosphate in human blood platelets.
    Salzman EW
    Biochim Biophys Acta; 1977 Aug; 499(1):48-60. PubMed ID: 196670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory mechanism of dipyridamole on platelet aggregation ex vivo.
    Fukawa K; Saitoh K; Irino O; Ohkubo K; Hashimoto S
    Thromb Res; 1982 Aug; 27(3):333-40. PubMed ID: 6291192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic considerations on treatment of increased platelet aggregation in diabetic vasculopathic patients.
    Bizzi B; Leone G; Boni P
    Acta Diabetol Lat; 1974; 11(6):437-45. PubMed ID: 4469856
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of cyclic AMP in adenosine inhibition of intracellular calcium rise in human platelets. Comparison of adenosine effects on thrombin- and epinephrine-induced platelet stimulation.
    Feoktistov IA; Paul S; Hollister AS; Robertson D; Biaggioni I
    Am J Hypertens; 1992 Jun; 5(6 Pt 2):147S-153S. PubMed ID: 1321639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on platelet functions of derivatives of cyclic nucleotides.
    Pareti FI; Carrera D; Mannucci L; Mannucci PM
    Thromb Haemost; 1978 Apr; 39(2):404-10. PubMed ID: 209573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cartilage cyclic nucleotide phosphodiesterase: inhibition by anti-inflammatory agents.
    Newcombe DS; Thanassi NM; Ciosek CP
    Life Sci; 1974 Feb; 14(3):505-19. PubMed ID: 4363082
    [No Abstract]   [Full Text] [Related]  

  • 19. [Interactions of platelet inhibitors].
    Glusa E; Hoffmann A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):861-4. PubMed ID: 94879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of glucagon, dibutyryl adenosine 3',5'-cyclic monophosphate and phosphodiesterase inhibitors on rat liver phosphorylase activity and adenosine 3',5'-cyclic monophosphate levels.
    Ingebretsen C; Clark JF; Allen DO; Ashmore J
    Biochem Pharmacol; 1974 Aug; 23(15):2139-46. PubMed ID: 4369954
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.